Obesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: could myeloma be prevented with metformin treatment?

Detalhes bibliográficos
Autor(a) principal: Cunha Júnior, Ademar Dantas da
Data de Publicação: 2021
Outros Autores: Zanette, Dalila Lucíola, Pericole, Fernando Vieira, Saad, Sara Teresinha Olalla, Carvalheira, José Barreto Campello
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/46103
Resumo: Universidade Estadual de Campinas. Faculdade de Ciências Médicas. Departamento de Medicina Interna. Divisão de Oncologia. Campinas, SP, Brasil / Hospital de Câncer de Cascavel. União Oeste Paranaense de Estudos e Combate ao Câncer. Clínica de Oncologia e Hematologia. Cascavel, PR. Brasil / Universidade Estadual do Oeste do Paraná. Departamento de Medicina Interna. Cascavel, PR. Brasil.
id CRUZ_0fbade723abeb2e1e473a782abb863a6
oai_identifier_str oai:www.arca.fiocruz.br:icict/46103
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Cunha Júnior, Ademar Dantas daZanette, Dalila LucíolaPericole, Fernando VieiraSaad, Sara Teresinha OlallaCarvalheira, José Barreto Campello2021-02-18T23:21:02Z2021-02-18T23:21:02Z2021CUNHA JÚNIOR, Ademar Dantas da et al. Obesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: could myeloma be prevented with metformin treatment? Advances in Hematology, p. 1-7, 2021.1687-9112https://www.arca.fiocruz.br/handle/icict/4610310.1155/2021/6615684porHindawiObesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: could myeloma be prevented with metformin treatment?info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleUniversidade Estadual de Campinas. Faculdade de Ciências Médicas. Departamento de Medicina Interna. Divisão de Oncologia. Campinas, SP, Brasil / Hospital de Câncer de Cascavel. União Oeste Paranaense de Estudos e Combate ao Câncer. Clínica de Oncologia e Hematologia. Cascavel, PR. Brasil / Universidade Estadual do Oeste do Paraná. Departamento de Medicina Interna. Cascavel, PR. Brasil.Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Ciências e Tecnologias Aplicadas em Saúde. Curitiba, PR, Brasil.Universidade de Campinas. Centro de Hematologia e Hemoterapia. Campinas, SP, Brasil.Universidade de Campinas. Centro de Hematologia e Hemoterapia. Campinas, SP, Brasil.Universidade Estadual de Campinas. Faculdade de Ciências Médicas. Departamento de Medicina Interna. Divisão de Oncologia. Campinas, SP, Brasil.Obesity is increasingly associated with the transformation of monoclonal gammopathy of undetermined significance (MGUS) into multiple myeloma (MM). Obesity, MGUS, and MM share common etiopathogenesis mechanisms including altered insulin axis and the action of inflammatory cytokines. Consistent with this interconnection, metformin could predominantly exert inhibition of these pathophysiological factors and thus be an attractive therapeutic option for MGUS. Despite the possible clinical significance, only a limited number of epidemiological studies have focused on obesity as a risk factor for MGUS and MM. (is review describes multiple biological pathways modulated by metformin at the cellular level and their possible impacts on the biology of MGUS and its progression into MM.Multiple MyelomaMonoclonal Gammopathy of Undetermined SignificanceObesityMetforminPharmaceutical PreparationsMieloma MúltipleGammopatía Monoclonal de Relevancia IndeterminadaObesidadMetforminaPreparaciones FarmacéuticasMyélome multipleGammapathie monoclonale de signification indéterminéeObésitéMetforminePréparations pharmaceutiquesMieloma MúltiploGamopatia Monoclonal de Significância IndeterminadaObesidadeMetforminaPreparações Farmacêuticasinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83084https://www.arca.fiocruz.br/bitstream/icict/46103/1/license.txt783568c2893d2e25a99990b126be1772MD51ORIGINAL6615684HindawiOK.pdf6615684HindawiOK.pdfapplication/pdf1770539https://www.arca.fiocruz.br/bitstream/icict/46103/2/6615684HindawiOK.pdff1bf50415e4632268225333db7b322f8MD52TEXT6615684HindawiOK.pdf.txt6615684HindawiOK.pdf.txtExtracted texttext/plain34670https://www.arca.fiocruz.br/bitstream/icict/46103/3/6615684HindawiOK.pdf.txte8c18caf3f5ada6e0165f9fafbcab323MD53icict/461032021-08-31 14:38:15.134oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352021-08-31T17:38:15Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Obesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: could myeloma be prevented with metformin treatment?
title Obesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: could myeloma be prevented with metformin treatment?
spellingShingle Obesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: could myeloma be prevented with metformin treatment?
Cunha Júnior, Ademar Dantas da
Multiple Myeloma
Monoclonal Gammopathy of Undetermined Significance
Obesity
Metformin
Pharmaceutical Preparations
Mieloma Múltiple
Gammopatía Monoclonal de Relevancia Indeterminada
Obesidad
Metformina
Preparaciones Farmacéuticas
Myélome multiple
Gammapathie monoclonale de signification indéterminée
Obésité
Metformine
Préparations pharmaceutiques
Mieloma Múltiplo
Gamopatia Monoclonal de Significância Indeterminada
Obesidade
Metformina
Preparações Farmacêuticas
title_short Obesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: could myeloma be prevented with metformin treatment?
title_full Obesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: could myeloma be prevented with metformin treatment?
title_fullStr Obesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: could myeloma be prevented with metformin treatment?
title_full_unstemmed Obesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: could myeloma be prevented with metformin treatment?
title_sort Obesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: could myeloma be prevented with metformin treatment?
author Cunha Júnior, Ademar Dantas da
author_facet Cunha Júnior, Ademar Dantas da
Zanette, Dalila Lucíola
Pericole, Fernando Vieira
Saad, Sara Teresinha Olalla
Carvalheira, José Barreto Campello
author_role author
author2 Zanette, Dalila Lucíola
Pericole, Fernando Vieira
Saad, Sara Teresinha Olalla
Carvalheira, José Barreto Campello
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Cunha Júnior, Ademar Dantas da
Zanette, Dalila Lucíola
Pericole, Fernando Vieira
Saad, Sara Teresinha Olalla
Carvalheira, José Barreto Campello
dc.subject.en.pt_BR.fl_str_mv Multiple Myeloma
Monoclonal Gammopathy of Undetermined Significance
Obesity
Metformin
Pharmaceutical Preparations
topic Multiple Myeloma
Monoclonal Gammopathy of Undetermined Significance
Obesity
Metformin
Pharmaceutical Preparations
Mieloma Múltiple
Gammopatía Monoclonal de Relevancia Indeterminada
Obesidad
Metformina
Preparaciones Farmacéuticas
Myélome multiple
Gammapathie monoclonale de signification indéterminée
Obésité
Metformine
Préparations pharmaceutiques
Mieloma Múltiplo
Gamopatia Monoclonal de Significância Indeterminada
Obesidade
Metformina
Preparações Farmacêuticas
dc.subject.es.pt_BR.fl_str_mv Mieloma Múltiple
Gammopatía Monoclonal de Relevancia Indeterminada
Obesidad
Metformina
Preparaciones Farmacéuticas
dc.subject.fr.pt_BR.fl_str_mv Myélome multiple
Gammapathie monoclonale de signification indéterminée
Obésité
Metformine
Préparations pharmaceutiques
dc.subject.decs.pt_BR.fl_str_mv Mieloma Múltiplo
Gamopatia Monoclonal de Significância Indeterminada
Obesidade
Metformina
Preparações Farmacêuticas
description Universidade Estadual de Campinas. Faculdade de Ciências Médicas. Departamento de Medicina Interna. Divisão de Oncologia. Campinas, SP, Brasil / Hospital de Câncer de Cascavel. União Oeste Paranaense de Estudos e Combate ao Câncer. Clínica de Oncologia e Hematologia. Cascavel, PR. Brasil / Universidade Estadual do Oeste do Paraná. Departamento de Medicina Interna. Cascavel, PR. Brasil.
publishDate 2021
dc.date.accessioned.fl_str_mv 2021-02-18T23:21:02Z
dc.date.available.fl_str_mv 2021-02-18T23:21:02Z
dc.date.issued.fl_str_mv 2021
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv CUNHA JÚNIOR, Ademar Dantas da et al. Obesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: could myeloma be prevented with metformin treatment? Advances in Hematology, p. 1-7, 2021.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/46103
dc.identifier.issn.pt_BR.fl_str_mv 1687-9112
dc.identifier.doi.pt_BR.fl_str_mv 10.1155/2021/6615684
identifier_str_mv CUNHA JÚNIOR, Ademar Dantas da et al. Obesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: could myeloma be prevented with metformin treatment? Advances in Hematology, p. 1-7, 2021.
1687-9112
10.1155/2021/6615684
url https://www.arca.fiocruz.br/handle/icict/46103
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Hindawi
publisher.none.fl_str_mv Hindawi
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/46103/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/46103/2/6615684HindawiOK.pdf
https://www.arca.fiocruz.br/bitstream/icict/46103/3/6615684HindawiOK.pdf.txt
bitstream.checksum.fl_str_mv 783568c2893d2e25a99990b126be1772
f1bf50415e4632268225333db7b322f8
e8c18caf3f5ada6e0165f9fafbcab323
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813009245764845568

Registros relacionados